Clinical trials: Clinical Trial, Phase I
Metastatic Castration-resistant Prostate Cancer
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel.
- Trial name
- TroFuse-01A (NCT07908524)
- Testing
- Sacituzumab tirumotecan, Rescue medication, Docetaxel
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes…
- Trial name
- NCT05881525
- Testing
- TC-N201 cells, IL-2, Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRCure Biopharma Ltd.
Advanced Solid Tumors
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an…
- Trial name
- DOMISOL (NCT06819735)
- Testing
- DT-7012, Immune checkpoint inhibitor
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 125 people
- Sponsor
- Domain Therapeutics Australia Pty Ltd
Healthy
Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
- Trial name
- NCT03083990
- Testing
- IBI305(Bevacizumab Biosimilar), Avastin(Bevacizumab)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hepatitis B
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.
- Trial name
- NCT02496897
- Testing
- FP-02.2 Vaccine, IC31® Adjuvant
- Where
- 21 sites in South Korea, United Kingdom
- Volunteers
- 61 people
- Sponsor
- Altimmune, Inc.
Advanced Solid Tumors
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.
- Trial name
- NCT06736327
- Testing
- SKB500
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Inflammatory Bowel Disease
A Clinical Study of SPH7854 Granules in Healthy Subjects.
To evaluate the safety of SPH7854 in healthy subjects.
- Trial name
- NCT06483373
- Testing
- SPH7854
- Where
- China
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Inguinal Hernia Repair
A Trial of HR18034 in Inguinal Hernia Repair
Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and efficacy of single postsurgical application of HR18034 compared with Naropin®
- Trial name
- NCT04551924
- Testing
- HR18034, Naropin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anal Fistula, Complex Perianal Fistulas
Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula
The purpose of this study is to evaluate the distribution and dynamic behavior of Nuclide labeled TH-SC01 cells in vivo in patients with perianal fistula
- Conditions
- Anal Fistula, Complex Perianal Fistulas, Crohn's Disease
- Trial name
- NCT06429241
- Testing
- Mesenchymal Stem Cells (MSCs)
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Prostate Cancer
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer
- Trial name
- NCT07468396
- Testing
- GLR2037
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Malignancies
Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.
This is a multi-center, phase I, open clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of TWP-102 injection in patients with advanced malignancies.
- Trial name
- NCT05024305
- Testing
- TWP-102 injection
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shandong TheraWisdom Biopharma Co., Ltd.
Solid Tumor Cancer
QLS5212 for Participants With Advanced Solid Tumors
This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally…
- Trial name
- NCT07467629
- Testing
- QLS5212
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04183166
- Testing
- TG4050
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Transgene
Prostate Cancer
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer.
- Trial name
- NCT00895466
- Testing
- PEP-223/CoVaccine HT
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Pepscan Therapeutics
Healthy Participants
Mass Balance Clinical Trial With TEV-56286
Mass balance clinical trial with TEV-56286
- Trial name
- NCT06627231
- Testing
- TEV-56286, [14C]-TEV-56286
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Advanced Solid Tumor Cancer
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in…
- Trial name
- LM364 (NCT07847905)
- Testing
- LM-364 for injection, Tislelizumab
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- LaNova Medicines Limited
Benign Renal Tumors, Malignant Renal Tumors
First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy
The objective of this pilot study will be to obtain a clinical safety and efficacy endpoint profile of laser tissue welding therapy for sealing the resected kidney surface after laparoscopic partial nephrectomy required for…
- Trial name
- LTW-KIDNEY (NCT02061605)
- Testing
- Laser Tissue Welding Device
- Where
- United States
- Sponsor
- Laser Tissue Welding, Inc.
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.